Latest news with #WhitMayo
Business Insider
2 days ago
- Business
- Business Insider
Leerink Partners Sticks to Their Hold Rating for Humana (HUM)
Leerink Partners analyst Whit Mayo reiterated a Hold rating on Humana yesterday and set a price target of $271.00. The company's shares closed yesterday at $220.41. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Mayo is a 3-star analyst with an average return of 1.7% and a 46.84% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, Tenet Healthcare, and UnitedHealth. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Humana with a $289.25 average price target, representing a 31.23% upside. In a report released yesterday, Barclays also downgraded the stock to a Hold with a $268.00 price target. The company has a one-year high of $406.09 and a one-year low of $206.87. Currently, Humana has an average volume of 1.75M.
Business Insider
4 days ago
- Business
- Business Insider
‘Time to Trust the Long-Term?' Analysts Maintain Buy on UnitedHealth Stock (UNH) Despite Price Target Cuts
UnitedHealth Group (UNH) is once again under scrutiny by Wall Street. Two analysts, David MacDonald from Truist Securities and Whit Mayo from Leerink Partners, lowered their price targets ahead of the company's Q2 earnings report, scheduled for July 29. This reflects growing concerns about near-term margin pressures and sector-wide volatility. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Nevertheless, both analysts maintain a Buy rating on UNH stock, citing confidence in long-term prospects. Truist Lowers Target but Sees Stability Ahead MacDonald lowered his price target on UnitedHealth to $345 from $360. The analyst expects Q2 results to show a mixed picture across the Healthcare sector, with some companies doing better than others depending on how they manage patient usage and costs. Despite these short-term pressures, he is optimistic about the long-term outlook due to strong demand for healthcare services. Also, the Reconciliation Bill has made the rules and regulations clearer, which could help stabilize the company's business going forward. Leerink Cuts Target but Projects Recovery by 2027 Leerink Partners' Mayo lowered the price target from $355 to $340, citing fading investor expectations as people wait for the company to update its 2025 financial guidance. He believes earnings in the $18–$19 per share range could ease concerns about shrinking margins. On the positive side, the analyst sees this as the start of a long-term recovery. He expects profit margins to improve gradually over the next few years, with stronger growth likely starting in 2027, once the company finishes switching out of its current Medicare risk model. Is UNH a Good Buy Right Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, seven Holds, and one Sell assigned in the last three months. At $357.14, the average UnitedHealth stock price target implies a 21.75% upside potential.
Yahoo
10-07-2025
- Business
- Yahoo
Leerink Partners Reiterates a Buy Rating on Ardent Health Partners (ARDT)
Ardent Health Partners, Inc. (NYSE:ARDT) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. Leerink Partners analyst Whit Mayo reiterated a Buy rating on Ardent Health Partners, Inc. (NYSE:ARDT) on July 5 without a price target. A healthcare professional wearing a health communications device discussing patient data with a colleague. The rating continued the analyst's bullish streak on the company, as he gave it a buy rating on June 23 due to strong sector trends and the belief that the company is presently underperforming its potential. The analyst stated that Ardent Health Partners, Inc. (NYSE:ARDT) has a strong outpatient network strategy with potential for growth. Mayo further reasoned that despite the delay in the anticipated $65 million NM DPP contribution to Q3 2025, the company's full-year EBITDA remains unaffected, attributing the delay to uncertainty in the timing of CMS approval instead of a lack of confidence in the eventual approval. Ardent Health Partners, Inc. (NYSE:ARDT) is a provider of healthcare and related services. The company is headquartered in Brentwood, TN, and also owns and operates hospitals through its subsidiaries. While we acknowledge the potential of ARDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
05-07-2025
- Business
- Business Insider
Leerink Partners Remains a Buy on Ardent Health Partners, Inc. (ARDT)
Leerink Partners analyst Whit Mayo reiterated a Buy rating on Ardent Health Partners, Inc. yesterday. The company's shares closed last Thursday at $13.39. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, Tenet Healthcare, and UnitedHealth. According to TipRanks, Mayo has an average return of 2.7% and a 49.39% success rate on recommended stocks. Ardent Health Partners, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $21.17, a 58.10% upside from current levels. In a report released on June 20, KeyBanc also maintained a Buy rating on the stock with a $24.00 price target.
Business Insider
05-07-2025
- Business
- Business Insider
Leerink Partners Keeps Their Buy Rating on Universal Health (UHS)
In a report released yesterday, Whit Mayo from Leerink Partners reiterated a Buy rating on Universal Health. The company's shares closed last Thursday at $184.53. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, UnitedHealth, and HCA Healthcare. According to TipRanks, Mayo has an average return of 2.7% and a 49.39% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Universal Health with a $229.09 average price target, implying a 24.15% upside from current levels. In a report released on June 24, Barclays also maintained a Buy rating on the stock with a $257.00 price target. Based on Universal Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.1 billion and a net profit of $316.68 million. In comparison, last year the company earned a revenue of $3.84 billion and had a net profit of $261.83 million Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UHS in relation to earlier this year. Most recently, in May 2025, Maria Singer Ruderman, a Director at UHS sold 1,097.00 shares for a total of $210,042.59.
